An open-label phase I/II study to assess the safety and immunogenicity of two doses of a Vero cell derived, whole virus clade 2 H5N1 influenza vaccine in healthy volunteers aged 21 to 45 years

Trial Profile

An open-label phase I/II study to assess the safety and immunogenicity of two doses of a Vero cell derived, whole virus clade 2 H5N1 influenza vaccine in healthy volunteers aged 21 to 45 years

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Oct 2015

At a glance

  • Drugs Influenza A vaccine H5N1-Baxter (Primary)
  • Indications Influenza A virus H5N1 subtype
  • Focus Pharmacodynamics; Registrational
  • Most Recent Events

    • 10 Nov 2011 Primary endpoint 'Neutralising-antibody-levels' has been met.
    • 23 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Oct 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top